It might take a while for this AI company to prove its worth, if it ever does so.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in. On January 12, Alec ...

Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

AI 制药上市公司 Recursion（NASDAQ: RXRX）宣布与英伟达（NVIDIA）建立了合作伙伴关系，并获得英伟达 5000 万美元的投资。 AI 制药上市公司 Recursion（NASDAQ: RXRX）宣布与英伟达（NVIDIA）建立了合作伙伴关系，并获得英伟达 5000 万美元的投资。 达成协议后，两家公司计划 ...

Recursion Pharmaceuticals Inc （纳斯达克：RXRX）董事Christopher Gibson于2026年1月20日以每股4.47美元的价格出售了40,000股A类普通股，总计178,800美元。

Recursion Pharmaceuticals (RXRX) closed at $4.65 in the latest trading session, marking a -4.12% move from the prior day.

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Recursion Pharmaceuticals (NASDAQ:RXRX) stands against the ...

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the ...